Inflammatory bowel disease (IBD) is a disease with unknown etiology that is characterized by uncontrolled intestinal inflammation and microbial dysbiosis. Qu Biologics’ Site Specific Immunomodulators (SSI) are a platform technology shown to improve the status of people living with IBD (Crohn’s disease and ulcerative colitis), with most of those patients showing clinical improvement also going […]

Qu Biologics is a clinical-stage biopharmaceutical company developing and evaluating an innovative immunotherapeutic approach to treating disease rooted in immune pathology/dysfunction. Qu’s proprietary technology platform, site-specific immunomodulators (SSI), act to stimulate the body’s own immune system to reverse the chronic inflammation underlying many conditions including cancer and immune-mediated diseases. For lung diseases, Qu’s platform SSI, […]

Inflammatory Bowel Disease (IBD) is thought to develop in people when their gut bacteria leak out of their intestines, and cause chronic gut inflammation. We recently found that the cells that line the guts of healthy people possess a specialized defense system called an inflammasome. In preliminary studies, the inflammasome seems to prevent the gut […]